Study links GLP-1 discontinuation to higher rates of heart attack, stroke and death
सिर्फ तथ्य

Study links GLP-1 discontinuation to higher rates of heart attack, stroke and death

सारांश

A retrospective cohort study of Italian type-2 diabetes patients found that stopping GLP-1 receptor agonists was associated with roughly double the risk of cardiovascular events and a five-fold increase in all-cause mortality compared with continued use.

A retrospective cohort study of 80,302 Italian patients with type 2 diabetes who began GLP-1 receptor agonist therapy found that 60.5% had stopped the medication by their last recorded visit. After propensity-score matching, researchers compared 28,713 patients who discontinued the drug with an equal number who remained on therapy. The discontinuation group experienced 3.94 events per 100 person-years for a composite endpoint of non-fatal myocardial infarction, non-fatal stroke or death, versus 1.96 events per 100 person-years among persistent users, yielding an incidence rate ratio of 2.01 (95% CI 1.77-2.28) and a hazard ratio of 2.03 (95% CI 1.92-2.14). All-cause mortality was markedly higher in the discontinuation group, with an incidence rate ratio of 4.67 (95% CI 4.11-5.30).

The risk increase was observed across body-mass-index categories, with hazard ratios of 1.61 (95% CI 1.47-1.78) for patients with BMI below 30 and 2.27 (95% CI 2.12-2.43) for those with BMI 30 or above. The study, led by Antonio Ceriello (IRCCS MultiMedica, Milan) and Antonio Nicolucci (CORESEARCH, Pescara), used data from the Associazione Medici Diabetologi database.

Previous research has reported discontinuation rates for GLP-1 agonists ranging from 37% to 81%, with many patients stopping within the first year due to gastrointestinal side effects, cost or inconvenience. Cardiologist and epidemiologist Christopher Labos told CTVNews.ca that gastrointestinal side effects are the primary driver of discontinuation, and that gradual dose escalation can improve tolerability. He cautioned that the observational design cannot prove causation, noting, “I don’t think it’s that stopping these drugs is causing the heart attacks. I think it’s that continuing these drugs lowers it.”

The authors suggest that discontinuation may signal higher underlying risk rather than directly causing adverse outcomes and call for more flexible dosing regimens to improve adherence. They also note that the findings do not apply to tirzepatide or to patients using GLP-1 agents solely for obesity management. Limitations include lack of data on reasons for stopping, socioeconomic factors, cause-specific mortality and incomplete heart-failure hospitalization records.

पहली बार यहां रिपोर्ट किया गया

पढ़ते रहें — निःशुल्क

समाचार फ़ॉलो करने के लिए मुफ़्त खाता बनाएँ। कार्ड की आवश्यकता नहीं।